Advanced Biomed Inc. (ADVB)
NASDAQ: ADVBHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADVB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.73M
- EPS (TTM)
- -$5.03
- Dividend yield
- None
- 52-week range
- 1.58 – 24.23
- Day range
- 1.58 – 1.76
- Volume / Avg
- 16.71K / 88.38K
- Beta
- —
- Shares outstanding
- 1.65M
52-week range
ADVB stock today
Advanced Biomed (ADVB) closed at $1.65 on Nov 20, down 5.71% (-$0.10), versus the S&P 500's 3.70% decline. Trading was light, with 16.71K shares changing hands, about 19% of the average daily volume. Shares are 93.2% below their 52-week high of $24.23, set on Jul 24, 2026 and 4.4% above the 52-week low of $1.58, near the bottom of the past year's range.
ADVB is down 71.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.8%. Advanced Biomed has posted a net loss over the last twelve months (EPS of -$5.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Advanced Biomed
Company profileAdvanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Xiaomin Chen Ph.D.
- Headquarters
- New York, NY
- Employees
- 31
- IPO year
- 2025
- Website
- advanbiomed.com
Financial highlights
Full financialsIn fiscal 2026, Advanced Biomed generated $127,637 in revenue. Net income was $6.7 million, for a net margin of 5231.3%. Operating margin was -4883.8%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue | $127.64K | — | — |
| Growth | — | — | — |
| Net income | $6.68M | $-3.26M | $-2.78M |
| EPS (diluted) | $5.33 | $-3.18 | $-0.14 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 18, 2026
- EPS actual vs est.
- $-0.60 vs —
Advanced Biomed peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BGLCBioNexus Gene Lab Corp | 0.68 | 0.00% | $1.99M | vs ADVB |
| ACONAclarion Inc. | 1.22 | -13.92% | $3.52M | vs ADVB |
| AMSAmerican Shared Hospital Services | 1.00 | -4.76% | $6.67M | vs ADVB |
| MDXHMDxHealth SA | 0.1074 | -8.52% | $10.25M | vs ADVB |
| SERASera Prognostics Inc. Class A | 1.81 | -4.23% | $71.98M | vs ADVB |
| BDSXBiodesix Inc. | 7.56 | -8.92% | $83.83M | vs ADVB |
| XGNExagen Inc. | 3.61 | -5.00% | $92.10M | vs ADVB |
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs ADVB |
Indexes, lists and sector
Advanced Biomed stock FAQ
What is Advanced Biomed's stock price today?
ADVB last traded at $1.65 as of Nov 20, 4:00 PM EST, down 5.71% on the day. Prices are delayed at least 15 minutes.
Does Advanced Biomed pay a dividend?
No. Advanced Biomed does not currently pay a regular cash dividend.
Who is Advanced Biomed's CEO?
Mr. Xiaomin Chen Ph.D. is the chief executive officer of Advanced Biomed Inc., which has about 31 employees.
Has ADVB ever split its stock?
Yes. The most recent ADVB stock split was a 1-for-20 split on Feb 20, 2026.
What is the ADVB 52-week high?
The 52-week high for ADVB is $24.23 and the 52-week low is $1.58. The stock is currently 93.2% below its high.